Disease relevance of Infant, Very Low Birth Weight

• Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low-birth-weight children aged 3 to 5 years [1].
• Pituitary-adrenal suppression and recovery in preterm very low birth weight infants after dexamethasone treatment for bronchopulmonary dysplasia [2].
• Low-dose indomethacin is recommended for the prevention of intraventricular hemorrhage in very low birth weight infants [3].
• Candidal sepsis and meningitis in a very-low-birth-weight infant successfully treated with fluconazole and flucytosine [4].
• Effects of early dexamethasone therapy on pulmonary mechanics and chronic lung disease in very low birth weight infants: a randomized, controlled trial [5].

Psychiatry related information on Infant, Very Low Birth Weight

• The authors investigated the validity of the Clinical Adaptive Test (CAT)/Clinical Linguistic and Auditory Milestone Scale (CLAMS) for developmental screening and early prediction in very low birth weight (VLBW) infants, using the Bayley Scales of Infant Development II (BSID-II) as a reference standard [6].

High impact information on Infant, Very Low Birth Weight

• METHODS: We compared the benefits and hazards of initiating dexamethasone therapy at two weeks of age and at four weeks of age in 371 ventilator-dependent very-low-birth-weight infants (501 to 1500 g) who had respiratory index scores (mean airway pressure x the fraction of inspired oxygen) of 52.4 at two weeks of age [7].
• Recombinant erythropoietin in very-low-birth-weight infants [8].
• G protein in very low birth-weight infants [9].
• Phenobarbitone for prevention of periventricular haemorrhage in very low birth-weight infants. A randomised double-blind trial [10].
• Ethamsylate reduces the incidence of periventricular haemorrhage in very low birth-weight babies [11].

Chemical compound and disease context of Infant, Very Low Birth Weight

• Low plasma retinol concentrations increase the risk of developing bronchopulmonary dysplasia and long-term respiratory disability in very-low-birth-weight infants [12].
• Cognitive outcome at 4 1/2 years of very low birth weight infants enrolled in the multicenter indomethacin intraventricular hemorrhage prevention trial [13].
• Trial of vitamin A supplementation in very low birth weight infants at risk for bronchopulmonary dysplasia [14].
• Glucose production and gluconeogenesis are negatively related to body weight in mechanically ventilated, very low birth weight neonates [15].
• Does phenobarbitone prevent periventricular hemorrhage in very low-birth-weight babies?: a controlled trial [16].

Biological context of Infant, Very Low Birth Weight

• Gluconeogenesis in very low birth weight infants receiving total parenteral nutrition [17].
• Breast-feeding (OR = 6.9; P = 0.001), very low birth weight (< 1500 g; OR = 6.3; P = 0.001) and p24 antigenaemia (OR = 4.6; P = 0.04) were all related to increased risk [18].
• Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life [19].
• The hCRH test in very low birth weight infants appears to be safe and reproducible, and produces a pituitary-adrenal response comparable to that seen in older children and adults, indicating that pituitary-adrenal function is mature at these early stages of gestation [20].
• Twenty-three very low-birth-weight infants of gestational age 26 to 28 weeks, whose serum T4 concentrations were 4 micrograms/dL on two occasions, and thyrotropin less than 20 microU/mL, were included in a double-blind study [21].

Anatomical context of Infant, Very Low Birth Weight

• The effects of parenteral L-carnitine supplementation on fat metabolism, nutrient intake, and plasma and erythrocyte carnitine concentrations were studied in 43 very low birth weight infants [22].
• It describes the early work determining the energy requirements of the preterm infant, the evolution of the use of human milk and its fortification for these infants, the development of special formulas for very-low-birth-weight infants and the various techniques/methods utilized including total parenteral nutrition [23].
• Angiotensin II type 1 receptor A1166C polymorphism and prophylactic indomethacin treatment induced ductus arteriosus closure in very low birth weight neonates [24].
• OBJECTIVES: The purpose of this study was to test the hypothesis that low circulating thyroxine concentrations characteristic of very low birth weight (VLBW) neonates (< 1500 g) are the result of decreased protein binding of thyroid hormones and to elucidate the mechanism(s) responsible and possible significance thereof [25].
• The effect of dexamethasone on time averaged mean velocity in the middle cerebral artery in very low birth weight infants [26].

Associations of Infant, Very Low Birth Weight with chemical compounds

• Effect of different vitamin A intakes on very-low-birth-weight infants [27].
• This study evaluates the need of vitamin E supplementation in very-low-birth-weight infants by long-term follow-up of plasma vitamin E status during the first 15 mo of life, with two different levels of supplementation [28].
• Very-low-birth-weight (VLBW) infants are susceptible to glutamine depletion because nutrition is limited in the first weeks of life [29].
• Pituitary-adrenal suppression in preterm, very low birth weight infants after inhaled fluticasone propionate treatment [30].
• Twenty-five preterm (< 32 gestational weeks), very low birth weight (< 1500 g) infants were randomized to receive inhaled fluticasone propionate (n = 13) or a placebo inhaler (n = 12) [30].

Gene context of Infant, Very Low Birth Weight

• Serial TAs were prospectively obtained from 36 very low birth weight infants and IL-4 and IL-13 concentrations were determined by ELISA [31].
• Lower prevalence of IL-4 receptor alpha-chain gene G variant in very-low-birth-weight infants with necrotizing enterocolitis [32].
• Serial TAs were obtained prospectively from 35 very low birth weight infants, and IL-8 and MCP-1 concentrations were determined by enzyme-linked immunoadsorbent assay [33].
• METHODS: We genotyped 123 very low birth weight (VLBW) infants for the tumour necrosis factor (TNF)- alpha G(-308)A, interleukin (IL)-1beta C(3954)T, IL-6 G(-174)C and IL-10 G(-1082)A SNPs [34].
• The pituitary-adrenal responses to exogenous human corticotropin-releasing hormone in preterm, very low birth weight infants [20].

Analytical, diagnostic and therapeutic context of Infant, Very Low Birth Weight

• To test the hypothesis that high-dose vitamin D2 supplementation would result in a lower incidence of radiographically detectable bone disease, we randomly assigned 40 very low birth weight infants to a control group who received vitamin D2 in a dosage of 400 IU/day and 41 to an experimental group who received a dosage of 2000 IU/day [35].
• CONCLUSIONS: A 42-day tapering course of dexamethasone decreases the duration of ventilator and oxygen dependency in very low birth weight infants and is not associated with an increased risk of short-term adverse effects [36].
• We conducted a prospective cohort study of 323 consecutively born very low birth weight infants (< or = 1499 gm) to determine any association between prenatal cocaine exposure and (1) intracranial ultrasonographic abnormalities and (2) other adverse perinatal outcomes [37].
• To evaluate the efficacy of four early intramuscular injections of vitamin E given in addition to continuous minimal oral vitamin E supplementation, 168 very low-birth-weight infants (less than or equal to 1,500 g) have enrolled in a randomized, double-masked, clinical study [38].
• The administration of a single intravenous injection of indomethacin was followed by a major constrictive effect on the ductus in 36 of 42 very-low-birth-weight (less than or equal to 1000 gm) infants with symptomatic patent ductus arteriosus (PDA) [39].

References